13,360 Shares in NeoGenomics, Inc. (NASDAQ:NEO) Acquired by Strategic Financial Concepts LLC

Strategic Financial Concepts LLC bought a new stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) during the 4th quarter, Holdings Channel reports. The firm bought 13,360 shares of the medical research company’s stock, valued at approximately $220,000.

A number of other institutional investors also recently added to or reduced their stakes in the business. Versant Capital Management Inc boosted its holdings in shares of NeoGenomics by 174.9% in the fourth quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 1,142 shares in the last quarter. Quarry LP bought a new position in NeoGenomics during the 3rd quarter valued at $40,000. Blue Trust Inc. increased its position in shares of NeoGenomics by 42.3% during the 3rd quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 987 shares during the period. KBC Group NV raised its stake in shares of NeoGenomics by 33.1% in the 3rd quarter. KBC Group NV now owns 4,530 shares of the medical research company’s stock worth $67,000 after buying an additional 1,127 shares in the last quarter. Finally, FMR LLC lifted its holdings in shares of NeoGenomics by 7.6% in the third quarter. FMR LLC now owns 13,255 shares of the medical research company’s stock valued at $196,000 after buying an additional 931 shares during the period. Institutional investors and hedge funds own 98.50% of the company’s stock.

Insider Buying and Selling at NeoGenomics

In other NeoGenomics news, General Counsel Alicia C. Olivo sold 5,175 shares of the firm’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $15.36, for a total transaction of $79,488.00. Following the completion of the transaction, the general counsel now owns 37,129 shares in the company, valued at $570,301.44. This trade represents a 12.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 1.30% of the company’s stock.

NeoGenomics Price Performance

NASDAQ NEO opened at $13.78 on Thursday. The stock has a 50-day simple moving average of $15.91 and a 200 day simple moving average of $15.64. The stock has a market capitalization of $1.77 billion, a PE ratio of -22.59 and a beta of 1.23. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.91 and a current ratio of 1.99. NeoGenomics, Inc. has a twelve month low of $12.13 and a twelve month high of $19.11.

Wall Street Analysts Forecast Growth

Several brokerages have commented on NEO. Jefferies Financial Group began coverage on shares of NeoGenomics in a research report on Tuesday, December 10th. They issued a “buy” rating and a $22.00 price target on the stock. Benchmark lowered shares of NeoGenomics from a “buy” rating to a “hold” rating in a research note on Monday, January 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price target on shares of NeoGenomics in a report on Friday, January 10th. The Goldman Sachs Group reduced their price objective on NeoGenomics from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Finally, Bank of America boosted their target price on NeoGenomics from $18.00 to $19.00 and gave the stock a “neutral” rating in a research report on Friday, December 13th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $20.20.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.